Vertex Pharmaceuticals (VRTX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, VRTX broke through the 20-day moving average ...

BOSTON, November 04, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2024, and raised its full-year ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report). The company’s shares closed yesterday at $472.80.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Investors with a lot of money to spend have taken a bullish stance on Vertex Pharmaceuticals VRTX. And retail traders should know. We noticed this today when the trades showed up on publicly ...

UBS has resumed coverage of Vertex Pharmaceuticals (NASDAQ:VRTX) with a buy rating, citing the company's growth potential. The investment bank said it believes Vertex (VRTX) has “best in sector ...

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INCORPORATED (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the ...

Vertex Pharmaceuticals (VRTX) closed the latest trading day at $484.94, indicating a +0.67% change from the previous session's end. This move lagged the S&P 500's daily gain of 0.77%. On the other ...